地拉罗司与去铁胺治疗重型β-地中海贫血铁过载患儿的临床疗效分析

Analysis of the Clinical Efficacy of Deferasirox and Deferoxamine in Children with Severeβ-thalassemia Iron Overload

目的研究和讨论地拉罗司和去铁胺对重型β-地中海贫血铁过载的治疗效果与价值。方法便利选取该院2017年1月-2018年6月期间内接受治疗的58例重型β-地中海贫血铁过载患儿作为此次研究的对象,采用随机数字表法将其分为对照组和观察组,每组29例。给予对照组患儿去铁胺治疗,给予观察组患儿地拉罗司治疗,治疗时间为6个月,对比两组患儿经过不用治疗方案之后的临床效果、心脏和肝脏磁共振成像(MRI)T2*检查结果。结果在经过6个月的治疗之后,观察组患儿的治疗效果显著优于对照组。两组总有效率比较差异无统计学意义(P>0.05)。其中,观察组总控制率为96.55%,高于对照组72.41%,两组数据之间差异统计学意义(P<0.05);观察组患儿的心脏(39.65±13.57)ms、肝脏(8.37±2.84)ms T2^*数据值显著比对照组心脏(31.56±12.49)ms、肝脏(3.84±2.01)ms高,两组数据之间存在明显差异有统计学意义(t=3.398,P=0.001;t=10.085,P=0.000)。结论将地拉罗司应用于重型β-地中海贫血铁过载的治疗中具有良好的效果,其临床效果显著高于去铁胺,去铁效果较好,对患儿身体的恢复有极大的促进作用,值得被广泛运用和推广。

Objective To study and discuss the therapeutic effect and value of deferasirox and deferoxamine on iron overload in severeβ-thalassemia.Methods 58 patients with severeβ-thalassemia iron overload who were treated in our hospital from January 2017 to June 2018 were convenient selected as the object of this study.They were divided into control group and observation group by random number table method,29 cases in each group.The patients in the control group were treated with deferoxamine and the patients in the observation group were treated with deferasirox.The treatment time was 6 months.The clinical effects,cardiac and liver magnetic resonance imaging(MRI)T2*check result of the two groups were compared after no treatment.Results After 6 months of treatment,the treatment effect in the observation group was significantly better than that in the control group.There was no significant difference in the total effective rate between the two groups(P>0.05).Among them,the total control rate in the observation group was 96.55%,which was higher than 72.41%in the control group.There was a significant difference between the two groups of data,which was statistically significant(P<0.05);the heart(39.65±13.57)ms,liver of the children in the observation group(8.37±2.84)ms;the value of T2*was significantly higher than that of the heart(31.56±12.49)ms and liver(3.84±2.01)ms in the control group.There was a significant difference between the two groups of data,with statistical significance(t=3.398,P=0.001;t=10.085,P=0.000).Conclusion The application of telarose in the treatment of severeβ-thalassemia iron overload has a good effect,and its clinical effect is significantly higher than that of desferrioxamine.The effect of desferrioxamine is better,which can greatly promote the recovery of children's body.The role is worthy of being widely used and promoted.